ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-4

BRONCHIAL ASTHMA: CLINICAL FEATURES, DIAGNOSTIC CRITERIA, AND MODERN TREATMENT STRATEGIES

Sayfiddinova Muhayyo
Termez branch of Tashkent medical academy
Norpulatova Moxira
Termez branch of Tashkent medical academy
Ismoilov Muxammadali
Termez branch of Tashkent medical academy

Relevance: Bronchial asthma remains one of the most prevalent and socially significant chronic respiratory diseases worldwide. According to the World Health Organization (WHO), asthma affects approximately 262 million people and caused over 461,000 deaths in 2019 alone. Despite advancements in medical technology, pharmacotherapy, and improved global access to healthcare, bronchial asthma continues to represent a major public health burden, particularly due to its chronic nature, rising incidence in both developed and developing countries, and the substantial economic impact of its management.

Asthma is a complex, heterogeneous disease characterized by chronic airway inflammation, reversible airflow limitation, and bronchial hyperresponsiveness. It typically manifests with episodic symptoms of wheezing, shortness of breath, chest tightness, and coughing that vary in intensity and over time. The clinical presentation and disease course are influenced by genetic predisposition, environmental triggers, comorbidities, and socioeconomic factors.

The chronicity of asthma and its frequent exacerbations compromise patients' quality of life, limit physical activity, impair academic and work performance, and increase the risk of hospitalizations and, in severe cases, mortality. Particularly vulnerable groups include children, the elderly, and individuals with comorbid allergic diseases or limited access to adequate medical care.

Over the past two decades, the approach to asthma diagnosis and treatment has undergone significant transformation. The Global Initiative for Asthma (GINA) has redefined asthma not as a singular condition, but rather as a syndrome with various phenotypes and endotypes requiring personalized treatment strategies. New medications, such as monoclonal antibodies targeting type 2 inflammation pathways (e.g., IL-5, IL-4/IL-13 inhibitors), have revolutionized the management of severe asthma. However, challenges persist in the form of underdiagnosis, poor adherence to therapy, environmental pollution, and the need for public health education and preventive measures.

This article aims to provide a comprehensive analysis of the current understanding of bronchial asthma, including its pathophysiology, classification, diagnostic criteria, and modern therapeutic approaches. Special emphasis will be placed on evidence-based treatment strategies, the role of biomarkers in asthma phenotyping, and the impact of lifestyle and environmental interventions on disease progression. Additionally, this paper will summarize key findings from recent clinical studies and highlight existing gaps in asthma care that require further research and policy attention.

Keywords: Bronchial asthma, airway inflammation, GINA guidelines, asthma exacerbation, phenotype, inhaled corticosteroids, biologic therapy, respiratory diseases, chronic illness, public health.

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-4

Research Objective: The objective of this study is to analyze the current clinical, diagnostic, and therapeutic aspects of bronchial asthma based on up-to-date medical literature and clinical research data. The specific aims are to:

- Evaluate the relevance of asthma as a global health issue;
- Examine the etiological and pathogenic mechanisms underlying asthma;
- Describe the diagnostic tools and criteria for asthma classification;
- Review current treatment modalities, including conventional pharmacotherapy and emerging biologic agents;
- Assess the effectiveness of these interventions in various patient populations;
- Identify ongoing challenges in asthma management and areas requiring further clinical research.

Materials and Methods: **This study is a narrative literature review combined with an analysis of recent clinical trials and population-based studies related to bronchial asthma. Sources include peer-reviewed medical journals, meta-analyses, randomized controlled trials (RCTs), guidelines from international health organizations (notably WHO and GINA), and national-level epidemiological data.**

The search terms included: *bronchial asthma*, *asthma phenotypes*, *GINA 2023*, *asthma treatment guidelines*, *biologic therapy for asthma*, *inhaled corticosteroids*, and *asthma prevalence*. Only English-language publications were included.

Inclusion and Exclusion Criteria

Included:

- Studies involving human participants diagnosed with bronchial asthma
- Clinical trials and meta-analyses evaluating pharmacologic or non-pharmacologic treatments
- Guidelines and consensus documents from recognized medical associations

Excluded:

- Animal studies or preclinical models
- Case reports
- Publications prior to 2015 (unless foundational)

Analytical Approach

Key findings were categorized based on the following clinical aspects:

1. **Epidemiology** and public health burden of asthma
2. **Pathophysiology and classification** of asthma endotypes
3. **Diagnostic tools and criteria**, including spirometry and biomarkers
4. **Pharmacologic management**, including ICS/LABA, LTRAs, and biologics
5. **Non-pharmacologic strategies**, such as lifestyle changes and environmental control

Data from high-quality randomized controlled trials and systematic reviews were prioritized to ensure the robustness of conclusions.

Research Results

1. Epidemiology and Public Health Burden

Recent WHO data (2023) indicate that bronchial asthma affects over **300 million people worldwide**, with particularly high prevalence in children and adolescents. In industrialized nations, up to **10% of the pediatric population** is diagnosed with asthma. The burden is exacerbated in low- and middle-income countries due to limited diagnostic resources and inconsistent treatment availability.

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

THE MULTIDISCIPLINARY JOURNAL OF SCIENCE AND TECHNOLOGY

VOLUME-5, ISSUE-4

Hospital admission rates for asthma exacerbations remain high, especially among populations with poor disease control. Moreover, asthma accounts for significant **indirect costs** (e.g., absenteeism, reduced productivity) in national health expenditures.

2. Clinical Phenotypes and Endotypes

Asthma is now understood as a **syndrome** with diverse phenotypes:

- **Allergic (early-onset) asthma**: common in children, often with comorbid atopic dermatitis and allergic rhinitis
- **Non-allergic asthma**: characterized by neutrophilic inflammation and poorer response to corticosteroids
- **Late-onset eosinophilic asthma**: more common in adults, often associated with nasal polyposis
- **Exercise-induced asthma**: typically seen in athletes and active children
- **Obesity-associated asthma**: marked by low-grade systemic inflammation and steroid resistance

These phenotypes correspond to distinct **endotypes** (e.g., Th2-high, Th2-low) that guide targeted therapy.

3. Diagnostic Tools and Challenges

The primary diagnostic tool remains **spirometry**, demonstrating **reversible airflow obstruction** (FEV_1 increase ≥12% post-bronchodilator). However, spirometry is underutilized, especially in primary care.

Other diagnostic aids include:

- **Fractional exhaled nitric oxide (FeNO)**: marker of eosinophilic inflammation
- **Blood eosinophil count**: used to predict response to biologic therapies
- **Peak expiratory flow monitoring**: useful in tracking variability

Diagnosis is complicated by asthma mimickers (e.g., vocal cord dysfunction, GERD), and **underdiagnosis** is common in children and elderly patients.

Conclusion: Bronchial asthma continues to pose a significant public health challenge worldwide due to its chronic nature, rising incidence, and economic burden. Despite substantial progress in understanding its pathogenesis and clinical heterogeneity, gaps remain in both diagnosis and long-term disease control.

Modern medicine no longer treats asthma as a singular entity but rather as a collection of syndromic conditions with diverse phenotypes and endotypes. This paradigm shift has enabled the development of **personalized treatment strategies**, particularly for patients with severe asthma, through the introduction of **biologic therapies** targeting specific inflammatory pathways. However, the **successful management of asthma** still hinges on basic principles: early diagnosis, correct inhaler use, environmental control, patient education, and ongoing follow-up.

The GINA 2023 guidelines advocate for a patient-centered approach that emphasizes shared decision-making, proactive symptom monitoring, and flexible treatment adjustments based on asthma control levels. Regular use of low-dose ICS-formoterol as both maintenance and rescue therapy (MART approach) is now preferred over traditional SABA monotherapy due to superior safety and efficacy outcomes.

Nevertheless, challenges such as **underdiagnosis**, **poor treatment adherence**, **limited access to biologics**, and environmental triggers (e.g., pollution, allergens) continue to compromise asthma control, especially in vulnerable populations. In addition, the increasing prevalence of asthma in

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 2022-2.889,
2024-6.875 ResearchBib IF: 9.948 / 2024

children and the elderly calls for **age-specific strategies** that account for cognitive, physiological, and socioeconomic differences.

Future directions in asthma research should focus on:

- Further refining endotype-specific biomarkers for therapy guidance;
- Exploring gene-environment interactions;
- Integrating digital health tools and AI-assisted monitoring;
- Ensuring equitable access to asthma care and medication globally.

In conclusion, while bronchial asthma remains a lifelong condition for many patients, current advances in **clinical practice, pharmacotherapy, and education** offer significant opportunities to achieve full disease control and improve quality of life. Multidisciplinary collaboration among clinicians, researchers, public health institutions, and policymakers is essential to meet the WHO goal of reducing the global asthma burden.

References:

1. Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention — 2023 Update*. Available from: https://ginasthma.org

2. World Health Organization. *Asthma: Key facts*. Geneva: WHO; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/asthma

3. Boulet LP, Reddel HK, Bateman ED, et al. The evolution of asthma guidelines: A global perspective. *Lancet Respir Med*. 2022;10(3):233–244.

4. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: A European Respiratory Society/American Thoracic Society guideline. *Eur Respir J*. 2020;55(1):1900588.

5. Pavord ID, Beasley R, Agusti A, et al. After asthma: Redefining airways diseases. *Lancet*. 2018;391(10118):350–400.

6. Hanania NA, Wenzel S, Rosén K, et al. Exploring the efficacy and safety of dupilumab in patients with uncontrolled persistent asthma: *Lancet*. 2016;388(10039):31–44.